MD4481B1 - Herpesvirus recombinant Koi (KHV) şi vaccin pentru profilaxia bolii cauzate de KHV - Google Patents

Herpesvirus recombinant Koi (KHV) şi vaccin pentru profilaxia bolii cauzate de KHV

Info

Publication number
MD4481B1
MD4481B1 MDA20120127A MD20120127A MD4481B1 MD 4481 B1 MD4481 B1 MD 4481B1 MD A20120127 A MDA20120127 A MD A20120127A MD 20120127 A MD20120127 A MD 20120127A MD 4481 B1 MD4481 B1 MD 4481B1
Authority
MD
Moldova
Prior art keywords
khv
prevention
vaccine
koi herpesvirus
disease caused
Prior art date
Application number
MDA20120127A
Other languages
English (en)
Russian (ru)
Other versions
MD20120127A2 (ro
MD4481C1 (ro
Inventor
Алайн Францис Клод0 ВАНДЕРПЛАСШЕН
Original Assignee
Gesval S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gesval S.A. filed Critical Gesval S.A.
Publication of MD20120127A2 publication Critical patent/MD20120127A2/ro
Publication of MD4481B1 publication Critical patent/MD4481B1/ro
Publication of MD4481C1 publication Critical patent/MD4481C1/ro

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16021Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16041Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16051Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16061Methods of inactivation or attenuation
    • C12N2710/16062Methods of inactivation or attenuation by genetic engineering
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/20Pseudochromosomes, minichrosomosomes
    • C12N2800/204Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Farming Of Fish And Shellfish (AREA)

Abstract

Invenţia se referă la un herpesvirus atenuat recombinant viu Koi (KHV) şi poate fi utilizată pentru profilaxia şi/sau tratamentul terapeutic al bolii peştilor cauzate de herpesvirusul Koi la carpi, aşa ca Cyprinos carpio carpio sau Cyprinos carpio koi.Conform invenţiei, herpevirusul menţionat conţine o genă, în care cadrul de citire deschis 56 (ORF56) şi cadrul de citire deschis 57 (ORF57) au fost supuse mutaţiei. De asemenea, invenţia se referă la o metodă de obţinere a acestui tip de KHV, la celule ce conţin aşa KHV şi la utilizarea acestui KHV în calitate de vector şi în vaccinuri.
MDA20120127A 2011-12-30 2012-12-27 Herpesvirus recombinant Koi (KHV) şi vaccin pentru profilaxia bolii cauzate de KHV MD4481C1 (ro)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11196171 2011-12-30

Publications (3)

Publication Number Publication Date
MD20120127A2 MD20120127A2 (ro) 2013-07-31
MD4481B1 true MD4481B1 (ro) 2017-05-31
MD4481C1 MD4481C1 (ro) 2017-12-31

Family

ID=47429841

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20120127A MD4481C1 (ro) 2011-12-30 2012-12-27 Herpesvirus recombinant Koi (KHV) şi vaccin pentru profilaxia bolii cauzate de KHV

Country Status (18)

Country Link
US (2) US20140348875A1 (ro)
EP (1) EP2797627B1 (ro)
JP (3) JP5982009B2 (ro)
CN (1) CN104159609B (ro)
BR (1) BR112014016117A2 (ro)
HU (1) HUE053075T2 (ro)
IL (1) IL232902A0 (ro)
IN (1) IN2014CN04655A (ro)
MD (1) MD4481C1 (ro)
MX (1) MX361408B (ro)
PH (1) PH12014501388A1 (ro)
PL (1) PL2797627T3 (ro)
RS (1) RS61261B1 (ro)
RU (1) RU2662768C2 (ro)
SG (1) SG11201403066TA (ro)
TW (1) TWI484034B (ro)
UA (2) UA114719C2 (ro)
WO (1) WO2013098214A1 (ro)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61261B1 (sr) * 2011-12-30 2021-01-29 Gesval S A Rekombinantni koi herpesvirus (khv) i vakcina za prevenciju bolesti prouzrokovane khv
US11174468B2 (en) * 2016-04-08 2021-11-16 William Marsh Rice University Galactose utilization
RU2736472C2 (ru) * 2016-11-18 2020-11-17 Общество с ограниченной ответственностью "ЭКСИФАРМ" Химерный белок, синтетическая днк, кодирующая указанный белок, экспрессионный вектор, штамм-продуцент синтетической днк и способ получения плазмидной днк
CN112321685B (zh) * 2018-11-05 2022-02-18 深圳技术大学 用于鱼类预防或治疗CyHV-2感染的试剂及其应用
EP3662929A1 (en) * 2018-12-07 2020-06-10 IDT Biologika GmbH A recombinant koi herpesvirus (khv) and a diva vaccine for preventing and/or treating a disease caused by khv
CN110101854B (zh) * 2019-05-14 2022-08-02 四川农业大学 一种鲤疱疹病毒ⅲ型疫苗及其制备方法
CN110468111B (zh) * 2019-08-07 2022-06-17 西北农林科技大学 一种展示CyHV-2膜蛋白的重组杆状病毒及其制备方法和应用
CN110452926B (zh) * 2019-08-07 2022-06-17 西北农林科技大学 一种展示CyHV-2膜蛋白的重组杆状病毒及其制备方法和应用
CN113679832A (zh) * 2021-05-24 2021-11-23 苏州大学 一种利用冷冻干燥制备杆状病毒载鲤疱疹病毒ii型dna疫苗的方法
CN115960903B (zh) * 2022-12-23 2023-09-08 中国水产科学研究院淡水渔业研究中心 一种抑制CyHV-2病毒增殖的反义RNA组、重组载体和纳米粒递送系统及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0382271B1 (en) 1989-02-04 1994-12-21 Akzo Nobel N.V. Tocols as adjuvant in vaccine
DE19733364A1 (de) 1997-08-01 1999-02-04 Koszinowski Ulrich H Prof Verfahren zur Klonierung eines großen Virusgenoms
IL153775A0 (en) 2003-01-01 2003-07-31 Yissum Res Dev Co Immunizing fish against viral infection
JP2007223913A (ja) * 2006-02-21 2007-09-06 Kyoritsu Seiyaku Kk コイヘルペスウイルス病ワクチン
CN101495636B (zh) * 2006-04-13 2012-12-05 国立大学法人东京海洋大学 锦鲤疱疹病毒(khv)病用dna疫苗
WO2009027412A1 (en) 2007-08-28 2009-03-05 Universite De Liege A recombinant koi herpesvirus (khv) or cyprinid herpesvirus 3 (cyhv-3) and a vaccine for the prevention of a disease caused by khv/cyhv-3 in cyprinus carpio carpio or cyprinus carpio koi
DE102007041332A1 (de) * 2007-08-31 2009-03-05 Siemens Ag Transferchuck zur Übertragung, insbesondere von Wafern
RS61261B1 (sr) * 2011-12-30 2021-01-29 Gesval S A Rekombinantni koi herpesvirus (khv) i vakcina za prevenciju bolesti prouzrokovane khv

Also Published As

Publication number Publication date
TWI484034B (zh) 2015-05-11
MD20120127A2 (ro) 2013-07-31
IN2014CN04655A (ro) 2015-09-18
US20140348875A1 (en) 2014-11-27
MX2014008045A (es) 2014-10-24
PL2797627T3 (pl) 2021-06-28
RS61261B1 (sr) 2021-01-29
TW201333201A (zh) 2013-08-16
WO2013098214A1 (en) 2013-07-04
UA114719C2 (uk) 2017-07-25
JP2015503914A (ja) 2015-02-05
RU2662768C2 (ru) 2018-07-31
RU2014131474A (ru) 2016-02-20
JP2018078903A (ja) 2018-05-24
US9931396B2 (en) 2018-04-03
PH12014501388A1 (en) 2014-09-22
JP2016195593A (ja) 2016-11-24
CN104159609A (zh) 2014-11-19
EP2797627B1 (en) 2020-10-07
MX361408B (es) 2018-12-04
IL232902A0 (en) 2014-07-31
MD4481C1 (ro) 2017-12-31
HUE053075T2 (hu) 2021-06-28
SG11201403066TA (en) 2014-10-30
US20170028057A1 (en) 2017-02-02
EP2797627A1 (en) 2014-11-05
UA119786C2 (uk) 2019-08-12
CN104159609B (zh) 2018-05-22
JP5982009B2 (ja) 2016-08-31
BR112014016117A2 (pt) 2018-09-25

Similar Documents

Publication Publication Date Title
MD4481B1 (ro) Herpesvirus recombinant Koi (KHV) şi vaccin pentru profilaxia bolii cauzate de KHV
MX2016004063A (es) Variante de la proteina pcv2 orf2 y particulas similares al virus compuestas por esta.
TW201613954A (en) Interleukin-10 fusion proteins and uses thereof
MX359954B (es) Ácido nucleico que comprende o codifica para un asa troncal de histona y una secuencia poly (a) o una señal de poliadenilación para aumentar la expresión de un antígeno patogénico codificado.
NZ708144A (en) Recombinant adenoviruses and use thereof
SG10201907775QA (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
MX2013001613A (es) Métodos y composiciones para prevenir una afección.
MX2013007657A (es) Oligodesoxinucleotidos inmunoestimulantes.
PT2643345T (pt) Péptidos imunogénicos para utilizar na prevenção e/ou no tratamento de doenças infecciosas, doenças autoimunes, respostas imunitárias a alofatores, doenças alérgicas, tumores, rejeição de enxertos e respostas imunitárias contra vetores virais usados para a terapêutica de genes ou na vacinação genética
WO2010033798A3 (en) Live bacterial vaccines resistant to carbon dioxide (co2), acidic ph and/or osmolarity for viral infection prophylaxis or treatment
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
MX346596B (es) Oligodesoxinucleotidos inmunoestimuladores.
MX2011007692A (es) Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion.
BRPI0816134A2 (pt) Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença.
EP2528931A4 (en) CYCLOVIRUS AND USE METHOD THEREFOR
PH12017501100A1 (en) Recombinant swinepox virus and vaccines
WO2012078051A3 (en) IPN Vaccine
WO2012003320A3 (en) Flavivirus host-range mutations and uses thereof
MX363264B (es) Vectores de vacuna recombinante de herpesvirus bovino 1 (bohv-1) con baja virulencia.
MX360449B (es) Vacunas para el virus del papiloma humano y metodos para su uso.
WO2012149525A3 (en) Ureaplasma vaccine and antibody for prevention and treatment of human, animal and cell culture infection
MX2015011064A (es) Vacuna contra el virus de la leucemia bovina.
WO2010147971A3 (en) Il23 modified viral vector for recombinant vaccines and tumor treatment
TH158445A (th) รีคอมบิแนนท์คอยเฮอร์ปีส์ไวรัส (khv) และวัคซีนสำหรับการป้องกันของโรคที่ได้รับการทำให้เกิดขึ้นโดย khv

Legal Events

Date Code Title Description
GB9A Change of applicant (patent for invention)

Owner name: GESVAL S.A., BE AVENUE PRE-AILY, 4, B-4031 ANGLEUR

Free format text: PREVIOUS APPLICANT: UNIVERSITE DE LIEGE, BE AVENUE PRE-AILY, 4, B-4031 ANGLEUR, BELGIA

FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees